Is government action actually coming for the price of pharmaceuticals in the U.S.? It's been a campaign promise going back to 2015, from both sides of the political aisle, but nothing substantial has changed.

Janssen Biotech has entered into a definitive agreement to acquire a privately-held biopharmaceutical company focused on the red-hot field of cancer immunology.

Financial terms of the deal for BeneVir BioPharm are being kept confidential.

Students at UMB are looking to form new startups that will bring change to a range of different areas in healthcare and beyond, from the pockets where nurses keep supplies to the ways that drugs are delivered.

When Twist Bioscience Corp. started in Mission Bay five years ago with the idea of making synthetic genes for researchers, it consisted of Emily Leproust and her two co-founders. Today, the 240-employee company is priming to move to nearly 61,000 square feet in South San Francisco.

A pair of Baltimore-based tech leaders are joining the board of directors for TEDCO.

With the appointment by Gov. Larry Hogan, each will serve a four-year term on the board that oversees the state’s quasi-public agency backing early-stage tech companies.

"Commercializing Technologies for Societal Impact"

The governments of the United States of America (through the Department of State) and India (through the Department of Science & Technology) have established the United States - India Science & Technology Endowment Fund (USISTEF) for the promotion of joint activities that would lead to innovation and technopreneurship through the application of science and technology. The Endowment Fund activities are implemented and administered through the bi-national Indo-U.S. Science and Technology Forum (IUSSTF).

HC2 Holdings, Inc. (“HC2”) (NYSE:HCHC), a diversified holding company, announced today that BeneVir Biopharm, Inc. (“BeneVir”), a privately-held biotechnology company developing oncolytic immunotherapies for the treatment of cancer, has entered into a definitive agreement to be acquired by Janssen Biotech, Inc. (“Janssen”).

When: Thursday, May 17, 20184:00 - 7:00 PM EST
 
Where: University of Maryland BioPark, 801 West Baltimore Street, Baltimore, MD 21201

Join the fourth in the TEDCO funded Anchor Ventures events series for an important discussion about Talent. Our expert panel will discuss how to draw the right candidates to your company, the role personnel plays in the investment process, opportunities for enhancing your existing team, and the regional supply of entrepreneurial talent.

The National Institute of Standards and Technology is looking for the public’s help in refreshing how it uses research and development funds to help bring new products to market.

The digital health rocket seems to have gotten supercharged lately, at least when it comes to fundraising.  Depending on who you ask, either $1.62 billion (Rock Health’s count) or $2.5 billion (Mercom) or $2.8 billion (Startup Health’s count) was plowed into digital health companies in just the first three months of 2018.  By any measure Q1 2018 was the most significant quarter yet for digital health funding.  This headline has been everywhere.  Digital health:  to infinity and beyond!  But what is the significance of this? Should investors and customers of these companies be excited or worried?  It’s a little hard to tell.

One of the enduring mysteries of medicine is how individual genes, environment and lifestyle may combine to spark sickness or protect us from it. Unraveling this puzzle remains essential for scientists hoping to achieve the elusive goal of offering tailored treatments or personalized prevention plans.

Highmark Health announced today that through its VITAL Innovation Program, a test-and-learn platform, it will be evaluating WellDoc's® BlueStar® mobile app, an FDA-cleared, proven digital therapeutic for individuals with type 2 diabetes.

You've heard the word "blockchain" many times now, but probably not quite as many as you've heard the word "bitcoin." Yet you surely have a sense that the referents of those two words have a connection, and even if you haven't yet been interested in either, you may well know that blockchain, a technology, makes Bitcoin, a currency, possible in the first place. Their sheer novelty has already given rise to a mini-industry of explainer videos, more of them dealing directly with bitcoin than blockchain, but in time the latter could potentially overtake the former in importance, to the degree that it becomes as vital to society as the protocols that undergird the internet itself.

Scott Gottlieb, commissioner of the Food and Drug Administration, has introduced information technology initiatives under the agency’s data science incubator program during  the Health Datapalooza conference in Washington, D.C., MedCityNews reported Thursday.

It’s baaaaack, that reputation-shredding, stock-moving fight to the death over key CRISPR patents. On Monday morning in Washington, D.C., the U.S. Court of Appeals for the Federal Circuit will hear oral arguments in University of California v. Broad Institute. Questions?

The Baltimore Business Journal recognized Christy Wyskiel for her ongoing efforts to perfect the “magic formula” that will further catalyze the commercialization of life-changing research and technologies emerging from labs and dorms across Johns Hopkins.

A few years ago, Allysa Dittmar was about to go into surgery, but her interpreter didn’t show up.

Dittmar, who is deaf, was able to lip-read and recognize facial expressions during some of the mandated check that’s required before a procedure, but those were obscured when surgeons, nurses and anaesthesiologists, put on their masks. Things grew more frustrating, and the staff eventually gave up trying.

emocha Mobile Health’s video Directly Observed Therapy (DOT) platform helped patients with tuberculosis achieve 94 percent medication adherence with the potential to save public health programs $1,391 per patient on average, according to a new study conducted by researchers at the Johns Hopkins University School of Medicine published today in Open Forum Infectious Diseases. Staff and patients cited increased flexibility, convenience, and patient privacy compared to traditional treatment methods.

Illumina Accelerator, the genomics-focused startup accelerator backed by the publicly traded genetic sequencing pioneer Illumina Corp., has picked five startups for its seventh accelerator class, the company announced.

Wth technology addressing skin microbial therapeutics, fertility science, chronic disease alleviation, post traumatic stress disorder treatments, and services for the biopharmaceutical and clinical research industries; the startups selected by Illumina will have access to the company’s genomics and sequencing expertise, business coaching, lab and office space and an infusion of capital.

Please join us for our third lecture, “Understanding the Journey: The Past, Present, and Future of Cardiovascular Disease in Women " with Dr. Nanette Wenger of Emory University Division of Medicine. 

This year marks the 70th Anniversary of the establishment of the National Heart, Lung, and Blood Institute.

NHLBI began as the National Heart Institute on June 16, 1948, when President Harry S. Truman signed the National Heart Act. In 1969, the Institute expanded its mission (and name) to cover research on lung diseases, and in 1976, the Institute grew further to include blood disorders.

To commemorate the Institute's 70th anniversary and showcase important investments in scientific research, NHLBI will feature lectures throughout the year from prominent thought leaders representing areas of high scientific priority in heart, lung, blood, and sleep disorders.

United Therapeutics Corporation (NASDAQ: UTHR) and SteadyMed Ltd. (NASDAQ: STDY) announced today the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and an additional $2.63 per share in cash upon the achievement of a milestone related to the commercialization of Trevyent®. The transaction, including the $75 million in contingent consideration, is valued at $216 million.

The real world isn’t like Hollywood. Despite what we might see in TV shows like 24 or movies like Contagion, we don’t have teams of experts ready to spring into action at the first signs of a global outbreak.

But we should, philanthropist Bill Gates emphasized during his Shattuck Lecture for the Massachusetts Medical Society today. And Gates is ready to put up $12 million to help us get there.

Illumina announced on Thursday that it has selected five new startups for its accelerator program, which is now in its seventh funding cycle.

New technology is bringing the power of augmented reality into clinical practice. The system, called ProjectDR, shows clinicians 3D medical images such as CT scans and MRI data, projected directly on a patient’s skin.

An immunotherapy treatment — one that boosts the immune system — has improved survival in people newly diagnosed with the most common form of lung cancer (advanced non–small-cell lung cancer), according to an open-access study published in the New England Journal of Medicine.

Gubernatorial candidate Ben Jealous organized a meeting on Thursday that gave executives from Google and parent company Alphabet a chance to hear about technology in Baltimore and Prince George’s County.

Real-World Evidence (RWE) holds out the promise of reducing time and costs of product approvals, identifying new uses for existing products, increasing our ability to treat rare diseases, and improving clinical practices for using drugs and medical devices. The 21st Century Cures Act, enacted in 2016, requires FDA to evaluate the use of RWE in approving new drug indications. FDA in 2017 issued a final guidance document regarding RWE in regulatory decisions involving medical devices. The private sector is also focusing on RWE: more than half the pharmaceutical companies in a recent survey say they are significantly expanding their involvement in RWE. Nonetheless, misunderstandings and uncertainties remain, both about what constitutes RWE and its potential role in regulatory and other aspects of precision medicine.

Women and minorities are sparsely represented in our recent fundings. So what do we do about that?

As a business owner, I’m often asked to speak to groups about my entrepreneurial journey. One component of my talk involves the importance of long-term thinking. Too often, businesses and politicians fall into the trap of short-term thinking. They focus on making a profit this quarter or succeeding in their re-election campaign without considering the impact of their decisions five, 10 or 20 years down the road.

The University of Maryland, College Park is seeking a Director for its Office of Technology Commercialization.  The Director leads and manages the OTC, overseeing personnel, budgets, and all aspects of intellectual property cultivation, assessment, protection, and commercialization. The Director establishes and implements strategies to maximize the social and economic impact of University research and discoveries through OTC’s commercialization efforts and its support of related entrepreneurial endeavors. The Director is responsible for developing and meeting annual OTC licensing goals and acts as primary point of contact and steward to resolve problems and issues affecting intellectual property and licensing at all levels within the University.

In 2017, 25.7 percent of all angel capital group deals went to a founding team with at least one female founder, up from 17.0 percent in 2016, according to the Angel Resource Institute’s (ARI) HALO Report: 2017. The report also found a sizeable increase in the number of deals made for companies that included at least one minority female founder – 5.5 percent in 2017 (1.0 percent in 2016).

San Diego. New Haven. Boston.

Besides cities that make for a nice waterside vacation, these destinations seem to have figured out the complex, yet irresistible, world of bioscience investment.

The Biohealth Capital Region–DC, Maryland and Virginia – plans to be a top 3 biohealth hub in the US by 2023. What will it take to get there?

The Biohealth Capital Region is already a top 5 location as ranked by NIH and venture capital funding, patents, lab space, and jobs. The 1,100 participants at this week’s 2018 Biohealth Capital Region Forum agreed on the area’s strengths: a highly educated and diverse workforce, leading universities and research institutions, strong healthcare organizations, hundreds of companies, and broad-based policy commitment to the biohealth industry.

Competition held during 2018 BioHealth Capital Region Forum

Wilson Sonsini's Charlie Andres and BHI’s Rich Bendis present the team from Galen Robotics
 their award for winning the 2018 Crab Trap competition

ROCKVILLE, MARYLAND, April 26, 2018 – Galen Robotics, a Johns Hopkins University spinout, was chosen from five finalists as the company with the most commercial potential by judges at the 3^rd Annual Crab Trap Competition. This year’s judges included industry leaders Amgen’s Bethany Mancilla, AstraZeneca’s Shaun Grady, Blu Venture’s Dr. Paul Silber, J.P. Morgan’s John T. Rubin, New Enterprise Associates’ Sara Nayeem, Roche’s Robert Silverman, and Sands Capital Ventures’ Stephen Zachary. They were impressed with a presentation by Lead Hardware Engineer, Yunus Sevimli, on Galen Robotics’ low-cost, compact, and intuitive to use novel microsurgical robotic platform designed to assist surgeons with minimally-invasive applications in otolaryngology, neurosurgery and similar critical fields. Galen Robotics is the third Johns Hopkins University spinout to win this competition following  LifeSprout (2017) and Sonavex (2016).

Strong presentations also were made by the other finalists--AlgometRx, Cellth Systems, Renalert, and Reveragen Biopharma—whose technologies originated at Children’s National Medical Center, the University of Maryland, and Johns Hopkins University.

Are you involved in the fight against drug resistant bacteria?  Between June 1 and June 8^th, organizations seeking funding to advance antimicrobial technologies (diagnostics, therapeutics or devices) will have the opportunity to submit Expressions of Interest (EOI) to CARB-X.  CARB-X is dedicated to accelerating global antibacterial innovation through targeted funding of focused projects. Only technologies specifically focused on the Pathogens outlined in the CARB-X 2018 Funding Round 2 Scope will be considered.  Now is the time to beginning preparing your EOI.  More information is available on the CARB-X website: http://www.carb-x.org/application